Does decresaed perfusion of the brain play a role in the reduced funct
Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ?
What it found
A paper reports the results; we have not read it yet. See Papers below.
What it measured
Main measures
N-acetyl aspartate (NAA) levels after restoring the cerebral blood flow (CBF) with the endothelin-1 antagonist.
Other measures (1)
- Effects on the clinical disability and fatigue in MS patients
Fatigue
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: - Patients with the diagnosis of relapsing-remitting MS, according to the 2010 Revised Mc Donald Criteria Exclusion: - Clinical evidence of MS relapse within 3 months prior to inclusion.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Cerebral perfusion is globally decreased in patients with Multiple Sclerosis (MS) and might contribute to progressive axonal degeneration, cognitive decline and fatigue. In this placebo-controlled, double-blind, randomized trial with the endothelin-1 antagonist bosentan, we want to explore whether pharmacological restoration of cerebral blood flow (CBF) in patients with MS can improve axonal metabolism and clinical disability.
Papers
Loading reviews and guidelines…
History
Started
Jul 2017